Jun Hong Richard Chou

JUN HONG Richard CHOU is an accomplished professional in the pharmaceutical industry, currently serving as Vice President of R&D and Head of CMC at OBI Pharma, Inc. since April 2022, leading a team focused on CMC activities for large molecules, including antibodies and vaccines. Prior experience includes working as a Senior Chemist at the FDA's CDER/OPQ/OLDP from July 2018 to March 2022, where responsibilities encompassed scientific and regulatory reviews of CMC for ANDAs, risk assessments, and regulatory compliance. Previously, as a Chemist at the FDA from June 2014 to July 2018, Richard conducted lifecycle management and CMC reviews. Richard also held positions at Merck from August 2000 to May 2014, where contributions included material characterization and new product support. Richard's educational background includes a Ph.D. in Materials from Michigan State University and a post-doctoral fellowship at the University of Illinois, alongside degrees in Physical Organic Chemistry and Chemistry from Auburn University and National Cheng Kung University, respectively.